Target validation in drug discovery /

Target validation in drug discovery /

Saved in:

Bibliographic Details
Imprint:	Amsterdam ; Boston : Academic Press, ©2007.
Description:	1 online resource (xii, 279 pages) : illustrations
Language:	English
Subject:	Drug development. Drugs -- Testing. High throughput screening (Drug development) Drug development. Drugs -- Testing. High throughput screening (Drug development) Drug Design. Drug Delivery Systems. Technology, Pharmaceutical. Electronic books.
Format:	E-Resource Book
URL for this record:	http://pi.lib.uchicago.edu/1001/cat/bib/11153821

Hidden Bibliographic Details
Other authors / contributors:	Metcalf, Brian W. Dillon, Susan, 1952-
ISBN:	9780123693938 0123693934 9780080465975 0080465978
Digital file characteristics:	data file
Notes:	Includes bibliographical references and index. Print version record.
Summary:	This work presents a comprehensive contemporary framework for approaching target validation in drug discovery. It begins with a detailed description of new enabling technologies, including aptamers, RNA interference, functional genomics, and proteomics. The next section looks at biologic drug development with in-depth discussion of lessons learned from such well-known cases as Erbitux, Herceptin, and Avastin. Additional targets known as "second generation" drugs, which can be identified when disease pathways are validated by biologics, present new possible small molecule therapeutics and serve as the focus of the final section of the book.
Other form:	Print version: Target validation in drug discovery. Amsterdam ; Boston : Academic Press, ©2007 0123693934 9780123693938

Description
Summary:	This work presents a comprehensive contemporary framework for approaching target validation in drug discovery. It begins with a detailed description of new enabling technologies, including aptamers, RNA interference, functional genomics, and proteomics. The next section looks at biologic drug development with in-depth discussion of lessons learned from such well-known cases as Erbitux, Herceptin, and Avastin. Additional targets known as "second generation" drugs, which can be identified when disease pathways are validated by biologics, present new possible small molecule therapeutics and serve as the focus of the final section of the book.
Physical Description:	1 online resource (xii, 279 pages) : illustrations
Bibliography:	Includes bibliographical references and index.
ISBN:	9780123693938 0123693934 9780080465975 0080465978